Research programme: chemoattractant receptor Th2 antagonists - sanofi-aventisAlternative Names: SAR-398171
Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Mechanism of Action Prostaglandin D2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 13 Feb 2007 Preclinical trials in Asthma in France (unspecified route)